Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.550
Filtrar
2.
J Manag Care Spec Pharm ; 26(10): 1297-1300, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32996390

RESUMO

BACKGROUND: Three pharmacist-specific Current Procedural Terminology (CPT) codes exist to facilitate medication therapy management (MTM) reimbursement (codes 99605, 99606, and 99607). However, no studies have used CPT codes in administrative claims databases to identify subjects who have received MTM services. OBJECTIVE: To assess the prevalence of MTM services provided, using CPT codes identified in an administrative dataset. METHODS: A retrospective cohort study was conducted using a subset of Medicare Part D individuals from the IBM MarketScan Medicare Supplemental Research Databases (2009-2015). Researchers identified beneficiaries who received MTM services using CPT codes 99605, 99606, and 99607. RESULTS: Of the 16,483,709 individuals in the dataset, only 3,291 had CPT codes indicating that they received MTM services, representing an overall prevalence of 0.020%. CONCLUSIONS: The use of CPT codes as an indicator of MTM service provision resulted in far lower MTM utilization rates than in published literature. Reliance on CPT codes to identify MTM services in administrative claims is not recommended, given that it limited the researchers' ability to properly identify patient receipt of such services. More accurate methodologies are warranted for identifying MTM use and its effects on patient outcomes. DISCLOSURES: This work was supported by Pharmacy Quality Alliance; Merck Sharp & Dohme, a subsidiary of Merck & Co. (Kenilworth, NJ); and SinfoniaRx. The funding sources had no role in study design, collection, analysis, and interpretation of data, writing the report, or decision to submit the article for publication. Tate, Chinthammit, and Campbell completed this work during their employment at the University of Arizona. Pickering was an employee of Pharmacy Quality Alliance at the time of this study. Black is employed by Merck. Axon reports grants from the Arizona Department of Health Services and the American Association of Colleges of Pharmacy; Campbell reports a grant from the Community Pharmacy Foundation; Chinthammit reports fees from Eli Lilly; Black has received a grant from Merck; Warholak reports grants from the Arizona Department of Health Services and Novartis, all unrelated to this study. Taylor reports grants from Tabula Rasa Op-Co, during the conduct of the study, and from the Arizona Department of Health Services, outside the conduct of this study. This research was accepted as a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, May 16-20, 2020, in Orlando, FL, but was not presented due to the COVID-19 pandemic. An abstract was published in Value in Health, 2020;23(Suppl 1):S305.


Assuntos
Current Procedural Terminology , Coleta de Dados/métodos , Conduta do Tratamento Medicamentoso/estatística & dados numéricos , Humanos , Reembolso de Seguro de Saúde , Medicare Part D/estatística & dados numéricos , Estudos Retrospectivos , Estados Unidos
3.
Medicine (Baltimore) ; 99(35): e21723, 2020 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-32871892

RESUMO

BACKGROUND: Novel coronavirus pneumonia (COVID-19) has become a worldwide epidemic, causing huge loss of life and property. Because of its unique pathological mechanism, diabetes affects the prognosis of patients with COVID-19 in many aspects. At present, there are many controversies about whether angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) should be used in the treatment of patients with diabetes mellitus and COVID-19 comorbidities. There is an urgent need to provide evidence for the use of ACEI/ARB through high-quality systematic evaluation and meta-analysis. METHODS: We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Science and Technology Periodical Database, and Wanfang database using keywords related to COVID-19, diabetes mellitus, ACEI/ARB drugs, and randomized controlled trials . We will manually search gray literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies, extract data, and evaluate risk of bias. Data analysis will be conducted using the Review Manager software version 5.3.5 and stata 14.0 software for Mac. Statistical heterogeneity will be assessed using a standard chi-square test with a significance level of P < .10. Biases associated with study will be investigated using funnel plots. RESULTS: This study will provide a high-quality synthesis of efficacy and safety of ACEI/ARB drugs in patients with COVID-19 combined with diabetes mellitus, providing evidence for clinical treatment of diabetes mellitus combined with COVID-19. And the results will be published at a peer-reviewed journal. CONCLUSION: Our study will draw conclusions on the efficacy and safety of ACEI / ARB drugs in patients with diabetes mellitus complicated with covid-19, so as to provide theoretical guidance for clinical practice of diabetes mellitus with covid-19. INPLASY REGISTRATION NUMBER: INPLASY 202060111.


Assuntos
Antagonistas de Receptores de Angiotensina/farmacologia , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Infecções por Coronavirus , Diabetes Mellitus , Conduta do Tratamento Medicamentoso/normas , Pandemias , Pneumonia Viral , Betacoronavirus , Comorbidade , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/terapia , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/epidemiologia , Humanos , Pneumonia Viral/epidemiologia , Pneumonia Viral/terapia , Ensaios Clínicos Controlados Aleatórios como Assunto , Projetos de Pesquisa , Revisões Sistemáticas como Assunto , Resultado do Tratamento
4.
Curr Atheroscler Rep ; 22(11): 64, 2020 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-32870376

RESUMO

PURPOSE OF REVIEW: Statins are first-line therapy for lowering low-density lipoprotein (LDL) cholesterol in familial hypercholesterolemia (FH), particularly in heterozygous patients. We review advances and new questions on the use of statins in FH. RECENT FINDINGS: Cumulative evidence from registry data and sub-analyses of clinical trials mandates the value of statin therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) in FH. Statins are safe in children and adolescents with FH, with longer term cardiovascular benefits. The potentially toxic effects of statins in pregnancy need to be considered, but no association has been reported in prospective cohort studies with birth defects. There is no rationale for discontinuation of statins in elderly FH unless indicated by adverse events. FH is undertreated, with > 80% of statin-treated FH patients failing to attain LDL cholesterol treatment targets. This may relate to adherence, tolerability, and genetic differences in statin responsiveness. Statin treatment from childhood may reduce the need for stringent cholesterol targets. Combination of statins with ezetimibe and PCSK9 inhibitors significantly improves the efficacy of treatment. Whether statin use could improve the clinical course of FH patients with COVID-19 and other respiratory infections remains an unsolved issue for future research. Statins are the mainstay for primary and secondary prevention of ASCVD in FH. Sustained long-term optimal statin treatment from an early age can effectively prevent ASCVD over decades of life. Despite their widespread use, statins merit further investigation in FH.


Assuntos
Infecções por Coronavirus/epidemiologia , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Hiperlipoproteinemia Tipo II , Conduta do Tratamento Medicamentoso , Pneumonia Viral/epidemiologia , Anticolesterolemiantes/classificação , Anticolesterolemiantes/farmacologia , Betacoronavirus , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Humanos , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Hiperlipoproteinemia Tipo II/epidemiologia , Pandemias
5.
Aust J Gen Pract ; 49(8): 530-532, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32738870

RESUMO

BACKGROUND: During the COVID-19 pandemic, vulnerable and older people with chronic and complex conditions have self-isolated in their homes, potentially limiting opportunities for consultations to have medications prescribed and dispensed. OBJECTIVE: The aim of this article is to describe initiatives to ensure ongoing access to medications during the COVID-19 pandemic. DISCUSSION: Cooperation between wholesalers and purchase limits in pharmacies have helped to ensure supply of essential medications. Therapeutic substitution by pharmacists is permitted for specific products authorised by the Therapeutic Goods Administration. Prescribers are permitted to issue digital image prescriptions, and implementation of electronic prescribing has been fast-tracked. Expanded continued dispensing arrangements introduced during the bushfire crises have been temporarily extended. Pharmacists are permitted to provide medication management reviews via telehealth. A Home Medicines Service has been introduced to facilitate delivery of medications to people who are vulnerable or elderly. Anticipatory prescribing and medication imprest systems are valuable for access to end-of-life medications within residential aged care.


Assuntos
Infecções por Coronavirus , Medicamentos Essenciais/provisão & distribução , Acesso aos Serviços de Saúde/organização & administração , Conduta do Tratamento Medicamentoso , Pandemias , Assistência Farmacêutica , Pneumonia Viral , Idoso , Austrália/epidemiologia , Betacoronavirus , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Prescrição Eletrônica , Humanos , Conduta do Tratamento Medicamentoso/organização & administração , Conduta do Tratamento Medicamentoso/tendências , Múltiplas Afecções Crônicas/terapia , Pandemias/prevenção & controle , Assistência Farmacêutica/organização & administração , Assistência Farmacêutica/tendências , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , Telemedicina/métodos , Telemedicina/organização & administração , Telemedicina/tendências
6.
Obstet Gynecol ; 136(4): 823-826, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32769659

RESUMO

Recent evidence supports the use of an early, short course of glucocorticoids in patients with COVID-19 who require mechanical ventilation or oxygen support. As the number of coronavirus disease 2019 (COVID-19) cases continues to increase, the number of pregnant women with the disease is very likely to increase as well. Because pregnant women are at increased risk for hospitalization, intensive care unit admission, and mechanical ventilation support, obstetricians will be facing the dilemma of initiating maternal corticosteroid therapy while weighing its potential adverse effects on the fetus (or neonate if the patient is postpartum and breastfeeding). Our objective is to summarize the current evidence supporting steroid therapy in the management of patients with acute respiratory distress syndrome and COVID-19 and to elaborate on key modifications for the pregnant patient.


Assuntos
Infecções por Coronavirus , Cuidados Críticos/métodos , Glucocorticoides , Conduta do Tratamento Medicamentoso/normas , Pandemias , Pneumonia Viral , Complicações Infecciosas na Gravidez , Betacoronavirus/isolamento & purificação , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/terapia , Monitoramento de Medicamentos/métodos , Feminino , Maturidade dos Órgãos Fetais/efeitos dos fármacos , Glucocorticoides/classificação , Glucocorticoides/farmacologia , Humanos , Recém-Nascido , Oxigenoterapia/métodos , Pneumonia Viral/epidemiologia , Pneumonia Viral/terapia , Gravidez , Complicações Infecciosas na Gravidez/epidemiologia , Complicações Infecciosas na Gravidez/terapia , Complicações Infecciosas na Gravidez/virologia , Respiração Artificial/métodos , Medição de Risco
7.
Nephrol Nurs J ; 47(4): 319-371, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32830938

RESUMO

After consideration of risks and benefits, some patients with kidney failure choose conservative management. Conservative management of kidney failure (CM-KF) does not include dialysis or transplant and utilizes primarily pharmacologic strategies for symptom management, which can be challenging due to the number and complexity of symptoms. Additionally, there are safety concerns regarding altered pharmacokinetics and the adverse effects induced by some of the therapies that may be selected to treat symptoms. This review describes common kidney failure symptoms and provides recommendations for pharmacologic management in CM-KF. Selection of medication should be individualized to the patient and comorbidities, drug interactions, cost, and adverse effects should be carefully considered. Additional studies specifically focused on CM-KF are needed.


Assuntos
Tratamento Conservador , Conduta do Tratamento Medicamentoso , Insuficiência Renal/terapia , Humanos , Insuficiência Renal/enfermagem
8.
Future Oncol ; 16(28): 2191-2195, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32857603

RESUMO

Background: Telemedicine is seen as a savior during the COVID-19 pandemic. Materials & methods: This study is a descriptive cross-sectional study conducted with cancer patients who were interviewed via telemedicine from a tertiary care comprehensive oncology center. Results: A total of 421 patients were included in the study and 118 of them (28.0%) were >65 years old. Communication was provided most frequently by voice call (n = 213; 50.5%). The majority of the patients contacted by telemedicine had breast cancer (n = 270; 64.1%). For 135 patients (32.1%) no further examination or intervention was required and the previously planned follow-up visit was postponed by the clinician. Conclusion: This study showed that telemedicine could open a new era for medical oncology specialists.


Assuntos
Neoplasias da Mama/tratamento farmacológico , Sobreviventes de Câncer , Infecções por Coronavirus/prevenção & controle , Oncologia/organização & administração , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Telemedicina/organização & administração , Administração Oral , Adulto , Assistência ao Convalescente/métodos , Assistência ao Convalescente/organização & administração , Assistência ao Convalescente/normas , Assistência ao Convalescente/tendências , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/uso terapêutico , Betacoronavirus/patogenicidade , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/mortalidade , Neoplasias da Mama Masculina , Institutos de Câncer/organização & administração , Institutos de Câncer/normas , Institutos de Câncer/tendências , Neoplasias Colorretais/diagnóstico , Neoplasias Colorretais/tratamento farmacológico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/transmissão , Infecções por Coronavirus/virologia , Estudos Transversais , Feminino , Neoplasias dos Genitais Femininos/diagnóstico , Neoplasias dos Genitais Femininos/tratamento farmacológico , Humanos , Controle de Infecções/organização & administração , Controle de Infecções/normas , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Oncologia/métodos , Oncologia/normas , Oncologia/tendências , Conduta do Tratamento Medicamentoso/organização & administração , Conduta do Tratamento Medicamentoso/normas , Conduta do Tratamento Medicamentoso/tendências , Pessoa de Meia-Idade , Pneumonia Viral/epidemiologia , Pneumonia Viral/transmissão , Pneumonia Viral/virologia , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/tratamento farmacológico , Telemedicina/normas , Telemedicina/tendências
9.
Drug Saf ; 43(8): 691-698, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32696429

RESUMO

The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this review is to describe the pharmacological mechanism, clinical evidence and prescribing guidelines concerning azithromycin in COVID-19 patients. There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in addition is not based on results from COVID-19 patients specifically. Therefore, this antibacterial should be considered only as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agreement. After the initial expectations raised by a small trial, more recent evidence has raised serious safety concerns on the use of hydroxychloroquine or chloroquine with azithromycin to treat COVID-19 patients, as all these drugs have arrhythmogenic potential. The World Health Organization has not made recommendations suggesting the use of azithromycin with hydroxychloroquine or chloroquine as treatment for COVID-19, but some national organisations have taken a different position, recommending this as first-line treatment. Several scientific societies, including the American College of Cardiology, have cautioned about the risks of this treatment in view of the lack of evidence concerning its benefits.


Assuntos
Azitromicina/farmacologia , Betacoronavirus , Coinfecção , Infecções por Coronavirus , Pandemias , Pneumonia Viral , Antibacterianos/farmacologia , Betacoronavirus/efeitos dos fármacos , Betacoronavirus/fisiologia , Coinfecção/diagnóstico , Coinfecção/tratamento farmacológico , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/imunologia , Humanos , Conduta do Tratamento Medicamentoso/normas , Seleção de Pacientes , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/epidemiologia , Pneumonia Viral/imunologia , Guias de Prática Clínica como Assunto , Resultado do Tratamento
11.
Enferm. foco (Brasília) ; 11(2): 96-102, jul. 2020. tab
Artigo em Português | LILACS, BDENF - Enfermagem | ID: biblio-1104179

RESUMO

Objetivo: Avaliar a prática da administração de medicamento endovenosa em pacientes adultos internados em hospital de doenças infectocontagiosas. Metodologia: Estudo descritivo, observacional, desenvolvido em hospital de referência em doenças infectocontagiosas de Fortaleza-CE. Foram realizadas 111 observações de profissionais de enfermagem procedendo à administração de medicamentos endovenosos em pacientes com idade > 18 anos. Resultados: As ações mais realizadas foram: lê a prescrição médica (100%), consegue entender a grafia médica (97,2%) e confere o medicamento relacionado à prescrição (90,6%). Entretanto, as menos executadas foram: acalmar o paciente (21,6%), realizar limpeza da bancada (13,5%), usar equipamento de proteção individual (18,9%), desinfetar ampola ou frasco ampola (11,7%). Conclusão: O estudo mostrou diagnóstico situacional da equipe de enfermagem na atuação do preparo e da administração de medicamentos, caracterizando segurança de pacientes no nível sofrível, segundo o índice de positividade. (AU)


Objective: To evaluate the practice of intravenous drug administration in adult patients hospitalized for infectious-contagious diseases. Methodology: Descriptive, observational study, developed at a referral hospital in infectious diseases of Fortaleza-CE. A total of 111 observations were made by nursing professionals on the administration of intravenous drugs in patients> 18 years of age. Results: The most accomplished actions were: read the medical prescription (100%), can understand the medical script (97.2%) and check the medication related to the prescription (90, 6%). However, the least performed were: calming the patient (21.6%), cleaning the workbench (13.5%), using personal protective equipment (18.9%), disinfect ampoule or ampoule vial (11.7%). Conclusion: The study showed a situational diagnosis of the nursing team in the preparation and administration of medications, characterizing patient safety at the level of suffering, according to the positivity index. (AU)


Objetivo: Evaluar la práctica de la administración de medicamentos endovenosa en pacientes adultos internados en el hospital de enfermedades infectocontagiosas. Metodología: Estudio descriptivo, observacional, desarrollado en un hospital de referencia en enfermedades infectocontagiosas de Fortaleza-CE. Fueron realizadas 111 observaciones de profesionales de enfermería procediendo a la administración de medicamentos endovenosos en pacientes con edad> 18 años. Resultados: Las acciones más realizadas fueron: lee la prescripción médica (100%), consigue entender la caligrafía médica (97,2%) y confirma el medicamento relacionado a la prescripción (90,6%). Sin embargo, las menos ejecutadas fueron: calmar al paciente (21,6%), realizar limpieza de la mesa de trabajo (13,5%), usar equipo de protección individual (18,9 %), desinfectar la ampolla o frasco ampolla (11,7%). Conclusión: El estudio mostró diagnóstico situacional del equipo de enfermería en la actuación de la preparación y de la administración de medicamentos, caracterizando seguridad de pacientes en el nivel sufrible, según el índice de positividad. (AU)


Assuntos
Infusões Intravenosas , Enfermagem , Conduta do Tratamento Medicamentoso , Segurança do Paciente
12.
Prev Chronic Dis ; 17: E74, 2020 07 30.
Artigo em Inglês | MEDLINE | ID: mdl-32730199

RESUMO

Medically underserved patients in rural areas are more vulnerable to poor health outcomes, including the risks associated with coronavirus disease 2019 (COVID-19). Pharmacists, student pharmacists, and other health care professionals are working together to implement new, innovative ways to deliver the same standard of care during the COVID-19 pandemic to these vulnerable patients. These services include telehealth with virtual and telephone medication therapy management sessions led by ambulatory care pharmacists and student pharmacists. Pharmacists, student pharmacists, and other health care professionals should continue to adapt to these new technologies to improve health outcomes for their patients during the pandemic.


Assuntos
Betacoronavirus , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Área Carente de Assistência Médica , Pandemias/prevenção & controle , Farmacêuticos/organização & administração , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , População Rural , Doença Crônica , Serviços Comunitários de Farmácia , Florida , Humanos , Conduta do Tratamento Medicamentoso/organização & administração , Papel Profissional , Telemedicina
13.
Pharm. pract. (Granada, Internet) ; 18(2): 0-0, abr.-jun. 2020. tab, graf
Artigo em Inglês | IBECS | ID: ibc-194051

RESUMO

BACKGROUND: Self-administered medication (SAM) is encouraged in many hospitals worldwide as it increases patients' knowledge and understanding of their medication, but the effects on other outcomes, e.g. compliance or medication errors, were unclear. OBJECTIVES: To compare medication knowledge, adherence, medication errors, and hospital readmission among inpatients receiving SAM education under the supervision of a multidisciplinary team (study group) with those receiving routine nurse-administered medication (control group). METHODS: This study was a PROBE design. Inpatients with chronic diseases were randomly allocated (1:1) to either the study group or the control group using stratified-block randomization. Knowledge of medications was measured at hospital discharge and at the first two follow-up visits; adherence was measured at the first two follow-up visits, medication errors while in hospital, and hospital readmission within 60 days after discharge. For normally distributed continuous outcomes, mean difference and 95%CI were estimated; otherwise the median and the Mann-Whitney test p-value were reported. The percentage difference and 95%CI were reported for binary outcomes. RESULTS: 70 patients were randomized (35 in each group); all received complete follow-up. Both groups were similar at baseline. Mean (SD) age (years) were 59.2 (11.0) for the study group and 58.3 (12.0) for the control group. Percentages of females in the respective groups were 54.3 and 60.0. Mean time from discharge to the first follow-up visit was two weeks in both groups and time to the second follow-up visit were 68.8 days (study group) and 55.0 days (control group). The study group had significantly higher medication knowledge than the control group at hospital discharge (of the 10-point scale, medians, 8.56 and 6.18, respectively, p < 0.001). The corresponding figures were similar in both groups at the first follow-up visit (medians, 8.25 and 6.26, respectively, p < 0.001). Adherence to medication at the first visit in the study group (percentage mean 92.50% (SD=5.33%)) was significantly higher than that in the control group (79.60% (SD=5.96%)), percentage mean difference 12.90%, [95%CI 10.20%:15.60%], p < 0.001. Medication knowledge and adherence were sustained at the second follow-up visit. During hospitalization, no medication errors were found in the study group, and minimal errors occurred in the control group (1.48%, [95%CI 0.68%:2.28%] of doses administered, p = 0.001). Hospital readmission within 60 days after discharge was significantly lower in the study group (11.4%) than that in the control group (31.4%), percentage difference 20.0% (95%CI 1.4%:38.6%), 1-side Fisher exact p = 0.039. CONCLUSIONS: Among in-patients with chronic diseases, SAM program significantly increased knowledge of and adherence to prescribed medications. Medication errors regarding administration errors were infrequent but significantly higher in the control group. SAM reduced hospital readmission within 60 after discharge


No disponible


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Autoadministração , Comunicação Interdisciplinar , Sistemas de Medicação/organização & administração , Conduta do Tratamento Medicamentoso , Estimativa de Kaplan-Meier , Erros de Medicação/prevenção & controle
15.
Yakugaku Zasshi ; 140(6): 827-838, 2020.
Artigo em Japonês | MEDLINE | ID: mdl-32475933

RESUMO

Japan passed a law that eliminated discrimination against persons with disabilities in 2016. Health care providers must comply with this law and are required to deepen their understanding of disabilities and take action to eliminate discrimination based on a higher level of awareness. Pharmacists need to better understand hearing disabilities to effectively communicate and provide medication education to deaf and hard of hearing (HH). This study examined the understanding about deaf and HH communities and the effects of learning through a lecture and hearing loss simulation experiences on 151 students in Daiichi University of Pharmacy to improve their understanding deaf and HH communities and ability to communicate effectively with deaf and HH patients in providing medication education in April 2018. Before the learning, 125 students indicated a lack of confidence in their ability to communicate medication education due to a lack of understanding. However, 26 students responded that they could communicate with deaf and HH patients despite their misunderstandings about deaf and HH communities and the features of such communication. After the learning 132 students indicated they had the confidence to interact with deaf and HH patients in communication for medication education. This study suggests that students need to learn about deaf and HH communities and develop communication skills to interact with them for medication education. Taking these steps may contribute to creating an educational program to facilitate communication and improve medication education for deaf and HH through effective communication by pharmacists.


Assuntos
Competência Clínica , Educação em Farmácia , Aprendizagem , Conduta do Tratamento Medicamentoso/educação , Pessoas com Deficiência Auditiva , Adulto , Comunicação , Feminino , Humanos , Masculino , Educação de Pacientes como Assunto , Inquéritos e Questionários , Adulto Jovem
16.
Drug Saf ; 43(8): 699-709, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32572842

RESUMO

The coronavirus disease 2019 (COVID-19) pandemic that hit the world in 2020 triggered a massive dissemination of information (an "infodemic") about the disease that was channeled through the print, broadcast, web, and social media. This infodemic also included sensational and distorted information about drugs that likely first influenced opinion leaders and people particularly active on social media and then other people, thus affecting choices by individual patients everywhere. In particular, information has spread about some drugs approved for other indications (chloroquine, hydroxychloroquine, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, favipiravir, and umifenovir) that could have led to inappropriate and therefore hazardous use. In this article, we analyze the rationale behind the claims for use of these drugs in COVID-19, the communication about their effects on the disease, the consequences of this communication on people's behavior, and the responses of some influential regulatory authorities in an attempt to minimize the actual or potential risks arising from this behavior. Finally, we discuss the role of pharmacovigilance stakeholders in emergency management and possible strategies to deal with other similar crises in the future.


Assuntos
Infecções por Coronavirus , Uso de Medicamentos/tendências , Disseminação de Informação , Pandemias , Pneumonia Viral , Saúde Pública , Atitude Frente a Saúde , Betacoronavirus , Infecções por Coronavirus/classificação , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/psicologia , Humanos , Disseminação de Informação/ética , Disseminação de Informação/métodos , Conduta do Tratamento Medicamentoso/ética , Conduta do Tratamento Medicamentoso/normas , Farmacovigilância , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/epidemiologia , Pneumonia Viral/psicologia , Saúde Pública/métodos , Saúde Pública/normas , Mídias Sociais/ética , Mídias Sociais/normas , Medicina Social/ética , Medicina Social/normas
17.
PLoS One ; 15(6): e0233486, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32497110

RESUMO

BACKGROUND: Most residents in elderly care homes in Sri Lanka do not receive formal, on-site, patient care services. OBJECTIVE: To evaluate the appropriateness of prescribing, dispensing, administration, and storage practices of medication used by residents in selected elderly care homes in Colombo District, Sri Lanka. METHODOLOGY: This was a prospective, cross-sectional, multi-center study of 100 residents with chronic, non-communicable diseases, who resided in nine selected elderly care homes in Sri Lanka. Medication histories were obtained from each resident/caregiver and the appropriateness of medications in their current prescription was reviewed using standard treatment guidelines. Prescriptions were cross-checked against respective dispensing labels to identify dispensing errors. Medication administration was directly observed on two separate occasions per resident for accuracy of administration, and matched against the relevant prescription instructions. Medication storage was also observed in terms of exposure to temperature and sunlight, the suitability of container, and adequacy of separation if using multiple medications. RESULTS: The mean age of residents was 70±10.5 years and the majority were women (72%). A total of 168 errors out of 446 prescriptions were identified. The mean number of prescribing errors per resident was 1.68±1.23 [median, 2.00 (1.00-3.00)]. Inappropriate dosing frequencies were the highest (37.5%;63/168), followed by missing or inappropriate medications (31.5%;53/168). The mean number of dispensing errors per resident was 15.9±13.1 [median, 14.0 (6.00-22.75)] with 3.6 dispensing errors per every medication dispensed. Mean administration errors per resident was 0.95±1.5 [median, 0.00 (0.00-1.00)], with medication omissions being the predominant error (50.5%;48/95). Another lapse was incorrect storage of medications (143 storage errors), and included 83 medications not properly separated from each other (58.0%). CONCLUSION: Multiple errors related to prescribing, dispensing, administration, and storage were identified amongst those using medication in elderly care homes. Services of a dedicated consultant pharmacist could improve the quality of medication use in elderly care homes in Sri Lanka.


Assuntos
Erros de Medicação/estatística & dados numéricos , Conduta do Tratamento Medicamentoso , Casas de Saúde , Segurança do Paciente , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Interações Medicamentosas , Armazenamento de Medicamentos , Feminino , Humanos , Prescrição Inadequada , Masculino , Sistemas de Medicação/organização & administração , Sistemas de Medicação/estatística & dados numéricos , Conduta do Tratamento Medicamentoso/organização & administração , Conduta do Tratamento Medicamentoso/estatística & dados numéricos , Pessoa de Meia-Idade , Estudos Prospectivos , Garantia da Qualidade dos Cuidados de Saúde , Sri Lanka
20.
Am J Health Syst Pharm ; 77(12): 901-902, 2020 06 04.
Artigo em Inglês | MEDLINE | ID: mdl-32372099
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA